Contents

Central Sleep ApneaEdit

Central sleep apnea (CSA) is a form of sleep-disordered breathing characterized by pauses in breathing during sleep that result from reduced or absent respiratory drive, rather than obstruction of the upper airway. Unlike obstructive sleep apnea, where the airway collapses, CSA stems from a dampened brain signal to breathe or from unstable breathing control that periodically suppresses ventilation. CSA can impair sleep quality, daytime alertness, and cardiovascular function, and it often signals an underlying health issue such as heart failure, stroke, brain injury, or the use of certain medications. Management typically requires addressing the root cause, alongside devices or therapies designed to stabilize breathing during sleep. In practice, CSA sits at the intersection of neurology, cardiology, and sleep medicine, and it is an area where health systems increasingly emphasize value and patient-centered care.

From a policy and practical care standpoint, CSA exemplifies how modern health care must balance effective treatment with cost, access, and robust clinical evidence. Treatments that improve symptoms and outcomes must be weighed against their costs and potential risks, while ensuring patients have access to appropriate diagnostic testing such as polysomnography. This balance is particularly pertinent when devices or drugs carry substantial price tags or harbor safety concerns that affect large patient populations.

Overview

  • Central sleep apnea is defined by repeated cessation or reduction of breaths during sleep caused by inadequate ventilatory drive. The central component distinguishes CSA from primarily obstructive types of sleep-disordered breathing.
  • Common patterns include primary CSA, Cheyne-Stokes respiration (a crescendo-decrescendo breathing pattern often linked with heart failure), and treatment-emergent CSA that can appear after certain interventions for sleep-disordered breathing.
  • CSA frequently coexists with underlying medical conditions such as heart failure, stroke, brain injury, COPD, or opioid use, and its presence often prompts a search for a contributing cause.
  • Diagnosis relies on a sleep study (polysomnography) and clinical assessment, followed by targeted treatment of both symptoms and underlying conditions.

Causes and pathophysiology

  • Mechanism: CSA arises from instability in the feedback control of breathing. The brain’s respiratory centers may temporarily fail to signal breathing, or the sensitivity to carbon dioxide may shift, producing periodic pauses in ventilation.
  • Major risk factors and associations:
    • Heart failure, particularly with reduced ejection fraction, where CSA and Cheyne-Stokes respiration are relatively common.
    • Stroke or brain injury that disrupts central control of breathing.
    • Opioid therapy, which can depress the central respiratory drive and provoke central apneas.
    • Aging and certain metabolic or neurologic conditions that affect the respiratory control system.
    • High altitude or chronic hypoxemia in some cases of sleep-disordered breathing.
  • Subtypes:
    • Idiopathic or primary CSA, in which no clear cause is identified.
    • Cheyne-Stokes respiration, a specific pattern often seen in advanced heart failure.
    • Opioid-induced central sleep apnea, resulting from drug effects on the brain’s respiratory centers.
    • Treatment-emergent CSA (TECSA), which can arise after initiating therapies for other sleep apnea patterns or after adjusting ventilatory support.
  • Distinction from obstructive sleep apnea: OSA is driven by a physical blockage of the upper airway, whereas CSA is due to insufficient respiratory effort. In practice, many patients have mixed or overlapping features and require careful evaluation.

Diagnosis

  • Sleep testing: CSA is detected primarily through polysomnography, which monitors brain activity, eye movements, heart rate, breathing effort, airflow, oxygen levels, and sometimes carbon dioxide levels. The central apnea index, the number of central apneas per hour of sleep, helps define the burden of CSA.
  • Clinical evaluation: Symptoms include excessive daytime sleepiness, fatigue, morning headaches, cognitive difficulties, and unrefreshing sleep. A clinician also assesses for contributing conditions such as heart failure, stroke history, kidney or liver disease, and substance use (notably opioids).
  • Differential diagnosis: Clinicians distinguish CSA from obstructive apnea and from mixed patterns where both central and obstructive events occur. In some cases, overnight testing may include capnography (measuring carbon dioxide) to better characterize ventilatory control during sleep.
  • Role of imaging and screening: Brain imaging or cardiac evaluation may be indicated to identify underlying causes. The involvement of cardiology is common when heart failure or other cardiovascular disease is suspected.

Treatment and management

  • Core approach: Treat the underlying condition (for example, optimize heart failure management, address stroke sequelae, or adjust opioid regimens), while employing therapies that stabilize breathing during sleep.
  • Ventilatory support:
    • CPAP (continuous positive airway pressure) and BiPAP (bilevel positive airway pressure) can reduce CSA in some patients, particularly when there is a mixed or partial central component, but are not universally effective for all CSA patterns.
    • Adaptive servo-ventilation (ASV) was a widely used modality for CSA and Cheyne-Stokes respiration; however, safety concerns emerged in certain patient groups, notably those with heart failure and reduced ejection fraction, where large trials indicated potential harms. As a result, guidelines and clinical practice have become more cautious about ASV in these patients.
    • Oxygen therapy may help some individuals by mitigating hypoxemia and stabilizing breathing, though it does not address the central drive itself and is not suitable for all patients.
  • Pharmacologic approaches:
    • Acetazolamide, a carbonic anhydrase inhibitor, can promote a mild metabolic acidosis that reduces central apneas in some patients, particularly at high altitudes or in idiopathic CSA; its use must consider side effects and comorbidities.
    • Theophylline and other respiratory stimulants have historical use but are limited by narrow therapeutic windows and side effects.
  • Opioid management:
    • In opioid-induced CSA, dose reduction, alternative analgesic strategies, or non-opioid therapies are essential components of management.
  • Lifestyle and supportive care:
    • Management of obesity, sedentary lifestyle, and cardiovascular risk factors contributes to overall sleep health and can influence CSA indirectly.
    • Behavioral strategies, sleep hygiene, and regular follow-up with sleep medicine specialists are important for monitoring response to therapy and adjusting treatment as needed.
  • Access and policy considerations:
    • Insurance coverage, cost-effectiveness, and device reimbursement influence treatment options in practice. Evidence-based practice and individualized care plans help ensure that patients receive therapies with proven benefit while minimizing unnecessary or high-cost interventions.

Controversies and debates

  • Safety and value of adaptive technologies: The safety concerns around ASV in patients with certain kinds of heart failure prompted re-evaluation of its use. Proponents stress that properly selected patients may benefit from ASV, with improvements in sleep quality and daytime function; critics highlight trial data showing potential harms in specific populations and call for tighter patient selection and post-market surveillance. This debate centers on balancing innovation with patient safety and cost-effectiveness.
  • Role of treating the underlying condition vs. relying on devices: A central tension is whether to prioritize aggressive management of heart failure or other etiologies versus deploying ventilatory support therapies. The right approach emphasizes diagnosing and treating the root cause, using devices or drugs as adjuncts when supported by robust evidence of meaningful outcome improvement.
  • Cost, access, and policy: Some critics argue that high-cost devices or therapies may not deliver commensurate value for every patient, especially in systems with finite resources. From a value-oriented perspective, decisions should be guided by high-quality randomized trials, patient-centered outcomes, and real-world effectiveness, with an emphasis on reducing unnecessary variation in care.
  • “Woke” criticisms and practical medicine: In public discourse, some critiques argue that health policy debates over sleep-disordered breathing tilt toward social or identity-focused concerns rather than clinical outcomes. A practical counterpoint is that the priority should be interventions backed by solid evidence that demonstrably improve health and function, while recognizing that healthcare policy must also address access, affordability, and appropriate risk management. When policy discussions emphasize outcomes and cost-effectiveness, this is often seen as aligning with a results-oriented approach rather than ideology.

See also